TABLE 4.
Antitumor research related to CIP2A downregulation.
| Compounds | Suppressed tumor cells | Inhibition of nude mice xenografts | Reduce resistance | References |
|---|---|---|---|---|
| CIP2A siRNA | Human tongue squamous cell carcinoma (SCC) cell line CAL 27 | Xenograft model of oral cancer cell CAL27 | — a | Cantini et al. (2013) |
| Bladder cancer cell (T24) | Xenograft model of bladder cancer cell T24 | — | Xue et al. (2013) | |
| Lapatinib | Breast cancer cell (HCC 1937; MDA-MB-468/MDA-MB-231) | — | — | Liu J et al. (2016) |
| Genistein | Breast cancer cell (MCF-7-C3 and T47D) | — | — | Zhao et al. (2016) |
| Fingolimod | Breast cancer cell (MDA-MB-231and BT-474) | Xenograft model of breast cancer cell MDA-MB-231 | — | Zhao et al. (2016) |
| Tamoxifen | Breast cancer cell (MDA-MB-231, MDA-MB-468, MDA-MB-453, and SK-BR-3) | Xenograft model of breast cancer cell MDA-MB-468 | — | Liu N et al. (2014) |
| Cucurbitacin B | Breast cancer cell (MCF-7/Adr) | — | Doxorubicin | Cai et al. (2016) |
| Glioblastoma multiform (GBM) cell, (DBTRG-05MG, U251MG, U118MG, U87MG, and LN229) | Xenograft model of GBM cell U118MG | — | Qin et al. (2018) | |
| Gastric cancer cell (SGC7901/DDP and SGC7901) | — | Cisplatin | Liu et al. (2017d) | |
| The t (8:21)-bearing AML cell line kasumi-1, acute promyelocytic leukemia (HL60), acute myelomonocytic leukemia (U937), chronic myelogenous leukemia (K562), and Burkitt’s lymphoma (Raji) and T-cell acute lymphoblastic leukemia (Molt-4) | Xenotransplantation model of AML cell | — | Ma et al. (2019) | |
| Human gefitinib-resistant NSCLC cell A549, NCI-H1299 (H1299), NCI-H1975 (H1975), NCI-H820 (H820), and human normal lung epithelial cell (16-HBE) | H1975 cell transplantation model | Gefitinib | Liu et al. (2019) | |
| Bortezomib | HNSCC cell (Ca9-22, SAS and SCC-25) | — | — | Lin et al. (2012) |
| Breast cancer cell (HCC-1937, MDA-MB-231 and MDA-MB-468) | Xenograft model of breast cancer cell HCC-1937 | — | Tseng et al. (2012) | |
| Colon cancer cell (LoVo) | Xenograft model of colon cancer cell LoVo | — | Ding et al. (2014) | |
| HCC cell (Sk-Hep1 and Huh-7) | — | Radiation | Huang L.P et al. (2012) | |
| Cervical cancer cell (SiHa) | (Bortezomib and radiation combination) xenograft model of cervical cancer cell SiHa | Radiation | Huang P et al. (2012) | |
| Leukemia cell (HL-60 and KG-1) | Xenograft model of leukemia cell HL-60 | — | Liu et al. (2013) | |
| Non-small cell lung cancer cell (HCC4006) | — | Erlotinib | Saafan et al. (2021) | |
| Bortezomib and its derivative | HCC cell (Huh-7, Hep3B and Sk-Hep1) | Xenograft model of HCC cell Huh-7 | Anti-death receptor 5 antibodies CS-1008 | Chen et al. (2010); Hou et al. (2013) |
| Carfilzomib | Leukemia cell (HL-60, KG-1, THP-1 and K562) | Xenograft model of Leukemia cell HL-60 and K562 | — | Liu et al. (2017a) |
| Ellagic acid | Lung adenocarcinoma cell HOP62 and H1975 (harboring L858R/T790M EGFR mutation) | Xenograft model of lung cancer cell HOP62 | — | Duan et al. (2019) |
| Polyphyllin I | NSCLC cell A549 and DDP-resistant A549/DDP cells | — | Cisplatin | Feng et al. (2019b) |
| GC cell (SGC7901, SGC7901/DDP and GES-1) | Xenograft model of GC cell SGC7901/DDP | Cisplatin | Zhang et al. (2018) | |
| PC cancer cell (PC3 and DU145) | Xenograft model of PC cell DU145 | — | Liu C.Y et al. (2018) | |
| Erlotinib | NSCLC cell (H358) | Xenograft model of NSCLC cell H358 | — | Wang C Y et al. (2014) |
| HCC (PLC5 and Hep3B) | — | — | Yu H.C et al. (2013) | |
| Erlotinib and its derivative | HCC (Sk-Hep1) | — | — | Chen et al. (2012) |
| Erlotinib derivative TD-19 | NSCLC cell (H460) | Xenograft model of NSCLC cell H460 | — | Chao et al. (2014) |
| Erlotinib derivative TD52 | HCC (PLC5, Huh-7, Hep3B, and Sk-Hep1) | Xenograft model of HCC cell PLC5 | — | Yu et al. (2014) |
| Triple-negative breast cancer (TNBC) cells (HCC-1937) | Xenograft model of TNBC cell MDA-MB-468 | — | Liu et al. (2017b) | |
| MDA-MB-231 and MDA-MB-468) | ||||
| Afatinib | NSCLC cell (H358 and H441) | Xenograft model of NSCLC cell H358 | — | Chao et al. (2015) |
| Celastrol | NSCLC cell (H1975 and A549) | Xenograft model of NSCLC cell H1975 and A549 | — | Liu et al. (2014b) |
| Chondrosarcomas (CS) cell (SW1353 and JJ012) | — | — | Wu et al. (2017) | |
| Ethoxysan-guinarine | NSCLC cell (H1975 and A549) | — | Cisplatin | Liu et al. (2014a) |
| CRC cell (SW620, SW480, HT29 and HCT116) | Xenograft model of CRC cells SW620 | — | Jin et al. (2018) | |
| Temsirolimus | Colon cancer cell (HCT-15 and SW480) | Temsirolimus and cetuximab combination xenograft model of colon cancer cell HCT-15 | Cetuximab | Wang H.W et al. (2014) |
| Euxanthone | CRC cell (HT29, HCT116, SW620, LOVO and SW480) | Xenograft model of CRC cells HT29 | — | Wang et al. (2018) |
| Gambogenic acid | HCC (Hep G2 and Bel-7402) | — | — | Yu et al. (2016) |
| Huaier polysaccharide (HP-1) | ccRCC cells (A498 and 786-O) | Xenograft model of ccRCC cells A498 | Sunitinib | Fang et al. (2019) |
| FTY720 | Neuroblastoma cell SK-N-AS (CRL-2137), SK-N-BE (2) (CRL-2271), SH-EP and WAC (2) | Xenograft model of neuroblastoma cells SH-EP and WAC (2) | — | Williams et al. (2019) |
| Medulloblastoma cell (D341, D384, and D425) | Xenograft model of medulloblastoma cells D341, D384, and D425 | — | Garner et al. (2018) | |
| 2,5-Dimethyl Celecoxib | Glioblastoma cell (LN229, A172, U251 and U87MG) | Xenotransplantation model of glioblastoma cell LN229 cells in nude mice | — | Gao et al. (2021) |
| Polyphyllins I and VII | NSCLC cell (A549 and A549/DDP) | — | Cisplatin | Feng et al. (2019b) |
| (+)-Cyanidan-3-ol | Squamous cell skin cancer (SCSC) cell (A431) | DMBA/TPA-induced SCSC and xenograft model of SCSC cell A431 | — | Monga et al. (2022) |
| A431 |
a
Unknown.